Eli Lilly to acquire AtaiBeckley for about $2.8 billion, up to $3.8 billion with milestones

Eli Lilly and Company / AtaiBeckley Inc. (LLY) — Eli Lilly and AtaiBeckley announced a definitive agreement for Lilly to acquire AtaiBeckley at $6.75 per share in cash, roughly $2.8 billion upfront and up to $3.8 billion including milestones, about a 40% premium to the recent VWAP.

The lead asset is BPL-003 (mebufotenin benzoate), an intranasal synthetic 5-MeO-DMT for treatment-resistant depression heading into Phase 3. Expected to close in Q3 2026 subject to shareholder and regulatory approval, the deal marks a landmark Big Pharma acquisition in psychedelics and a validating exit for the sector.

Source: prnewswire.com

For the rest of that week's sector news, read our week in review.